SCHEDULE 13G/A: Amphastar Pharmaceuticals Insiders Disclose Combined 24.8% Stake in Latest SEC Filing

Jack Y. Zhang, Mary Z. Luo, and Applied Physics & Chemistry Laboratories, Inc. (APCL) have filed an amended Schedule 13G, disclosing a combined beneficial ownership of 24.8% of Amphastar Pharmaceuticals, Inc.'s common stock as of December 31, 2024.

Summary

• Jack Y. Zhang and Mary Z. Luo, as a group, beneficially own an aggregate of 12,524,153 shares of Amphastar Pharmaceuticals, Inc. common stock, representing 24.8% of the class.
• This percentage is based on 48,081,433 shares of the Issuer's common stock outstanding as of November 1, 2024.
• Dr. Jack Y. Zhang's beneficial ownership includes 2,312,948 shares held of record by him, 1,586,973 shares issuable upon exercise of outstanding options within 60 days, 1,021,492 shares held by his spouse Mary Z. Luo, 775,061 shares from options exercisable by Dr. Luo, and 6,827,679 shares held by Applied Physics & Chemistry Laboratories, Inc. (APCL).
• Dr. Mary Z. Luo's beneficial ownership includes 1,021,492 shares held of record by her, 775,061 shares issuable upon exercise of outstanding options within 60 days, 2,312,948 shares held by her spouse Jack Y. Zhang, 1,586,973 shares from options exercisable by Dr. Zhang, and 6,827,679 shares held by APCL.
• Applied Physics & Chemistry Laboratories, Inc. (APCL) beneficially owns 6,827,679 shares, representing 14.2% of the class, over which Dr. Zhang, Dr. Luo, and The Bill Luobei Zhang 2004 Irrevocable Trust are the sole owners and have shared voting and dispositive power.

Sentiment

Score: 5

Explanation: The document is a routine beneficial ownership disclosure (Schedule 13G amendment) and does not contain performance or forward-looking statements that would typically influence sentiment. It primarily updates the public record on insider holdings.

Positives

• Significant insider ownership (24.8%) by key executives and their related entities suggests strong alignment of management interests with long-term shareholder value.
• The stability of a large insider stake can provide a degree of confidence in the company's long-term strategic direction.

Negatives

• Concentrated insider ownership could potentially limit the influence of other shareholders in corporate governance matters.
• A large insider stake might reduce the float of publicly traded shares, potentially impacting liquidity.

Risks

• The high concentration of ownership by Dr. Zhang, Dr. Luo, and their controlled entity (APCL) could lead to potential conflicts of interest between the controlling shareholders and minority shareholders.
• The significant insider control may make the company less attractive for potential acquisition or merger opportunities, limiting shareholder exit strategies.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of beneficial ownership by insiders and does not provide specific insights into broader industry trends or competitive dynamics within the pharmaceutical sector. However, significant insider ownership is a common characteristic in many established pharmaceutical companies, reflecting long-term commitment from founders or key management.

Related Party Transactions

• The filing details the beneficial ownership of Jack Y. Zhang and Mary Z. Luo, who are spouses, and their jointly controlled entity, Applied Physics & Chemistry Laboratories, Inc. (APCL).
• APCL's ownership is attributed to Dr. Zhang, Dr. Luo, and The Bill Luobei Zhang 2004 Irrevocable Trust, indicating a closely held family and trust structure controlling a significant portion of the company's shares.

Stakeholder Impact

• Shareholders: The significant insider ownership by Dr. Zhang and Dr. Luo, along with their controlled entity APCL, indicates a high degree of control over the company. This can align management's long-term interests with shareholders but may also limit the influence of minority shareholders in corporate decisions.

Key Dates

Keywords

Amphastar Pharmaceuticals, AMP, Schedule 13G, Beneficial Ownership, Insider Ownership, Jack Y. Zhang, Mary Z. Luo, Applied Physics & Chemistry Laboratories, APCL, SEC Filing, Common Stock, Pharmaceuticals